Elicidation of skin injury mechanism vesicant anticancer agents and establishment of clinical care

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460232
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: International University of Health and Welfare
• Principal Investigator: ASANO Satoshi 国際医療福祉大学, 薬学部, 教授 (70568063)
• Co-Investigator(Renkei-kenkyūsha): TAKEDA Toshiaki 岩手県立大学, 看護学部, 教授 (40305248)
• Research Collaborator: TAKAISHI Masaki 国際医療福祉大学, 薬学部, 講師
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 起壊死性抗がん剤 / 皮膚障害 / 罨法 / 酸化ストレス / ヒートショックプロテイン / 細胞骨格 / アポトーシス / 微小管機能阻害薬

Outline of Final Research Achievements

We clarified the mechanism of severe skin injury which is frequently observed by extravasation of microtubule function inhibitors, which are vesicant anticancer agents, and investigated appropriate prevention and care of skin disorder. Studies using cultured cells derived from human were thought to involve oxidative stress and collapse of cytoskeleton due to microtubule fragmentation in acute phase cell injury observed from the early stage of exposure. Cytotoxicity was significantly suppressed under the culture conditions corresponding to the cold compress (23 ℃). Adding an adrenocortical hormone agent suppresses the expression of IL-6 and is expected to suppress the inflammatory response, but cytotoxicity also appears in the steroid agent itself, so it is necessary to control the proper dose should be used.

Free Research Field

医療系薬学